Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Sep 4, 2025, 22:00Shivani Modi Highlights SOHO 2025 Study Linking Elevated WBC Counts to Increased Thrombosis Risk
-
Sep 4, 2025, 22:00Cancer, Clots and Communication: Register Now for The Upcoming Webinar on CAT!
-
Sep 4, 2025, 11:52PARTHENOPE Trial: A New Benchmark in Risk Score Validation
-
Sep 4, 2025, 09:46SOHO 2025: Exploring AI in Hematology and Oncology
-
Sep 4, 2025, 09:03Novartis Shares an Infographic for ITP from SOHO 2025
-
Sep 5, 2025, 12:55RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
-
Sep 5, 2025, 12:18Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg's Efficacy for Essential Thrombocythemia
-
Sep 5, 2025, 06:28Digital Twin Study Predicts Higher Thrombotic Recurrence with DOACs vs VKAs in APS Patients
-
Sep 4, 2025, 22:00Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
-
Sep 4, 2025, 13:28Ahmed Ata Explains Plaque Rupture vs Plaque Erosion: Red Thrombus in STEMI vs White Thrombus in NSTEMI
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 5, 2025, 03:18Pier Mannuccio Mannucci on How Green Spaces and Physical Activity Can Help Prevent Heart Failure
-
Sep 5, 2025, 02:15Abdul Mannan Explains How DOACs Can Confuse Lupus Anticoagulant Testing
-
Sep 4, 2025, 11:55Sumyea Kabir Highlights the Critical Role of Safe Donors in Blood Transfusion Safety
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast
-
Sep 3, 2025, 14:11Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most